Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8363486 | 0.81 | CYP2C19 (0.30) | EPHX1 | |
| SCHEMBL11819305 | 0.77 | CYP2C19 (0.30) | — | |
| SCHEMBL29827264 | 0.76 | GAA (0.33) | EPHX1MAPTHPGD | |
| SCHEMBL895754 | 0.75 | GRM4 (0.34) | CYP1A2POLBLMNA | |
| SCHEMBL8970744 | 0.75 | SLC6A4 (0.32) | MAPT | |
| SCHEMBL9556556 | 0.75 | SLC6A4 (0.32) | MAPT | |
| SCHEMBL29412651 | 0.75 | ARG1 (0.31) | — | |
| SCHEMBL1063404 | 0.74 | CYP2C19 (0.40) | EPHX1MAPTCYP1A2FFAR3POLB | |
| SCHEMBL2018073 | 0.72 | MAPT (0.33) | MAPTCYP1A2FFAR3POLBLMNA | |
| SCHEMBL2015443 | 0.72 | FFAR3 (0.37) | EPHX1FFAR3POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1826111-A | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS (US) | 2006-08-30 | — | — | CN | disclosed |
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6109537-A | Release rate modulator and method for producing and using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | EPHX1 1628/4885MAPT 3569/4885CYP1A2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.